Monday, January 4, 2010
MONDAY, Jan. 4 (HealthDay News) -- The radiolabeled peptide analog 64Cu-TP3805, which has a high affinity for the receptor for the oncogene product VPAC1, appears useful in identifying breast cancers with PET imaging, according to the results of an animal study published online Dec. 15 in the Journal of Nuclear Medicine.
Mathew L. Thakur, Ph.D., of the Kimmel Cancer Center in Philadelphia, and colleagues analyzed data from transgenic MMTVneu mice, which develop mammary tumors that overexpress VPAC1 receptor protein on the cell surfaces. The authors examined mice with CT scans, 18F-FDG PET as a control, and PET with 64Cu-TP3805.
From nine mice, the researchers found that both the 18F-FDG and 64Cu-TP3805 probes identified four tumors, and another four were visualized with 64Cu-TP3805 only. All eight tumors identified by 64Cu-TP3805 were malignant and expressed VPAC1 receptors in substantially greater quantity than normal tissue. The two tumors visualized by 18F-FDG, but not 64Cu-TP3805, were benign and did not express more VPAC1 receptors than normal tissue.
"On the basis of the data presented in this report and those published previously, it is reasonable to conclude that 64Cu-TP3805 has the ability to identify malignant lesions accurately, eliminate those benign masses that do not express the specific biomarkers of breast cancer, and likely contribute to the management of patients with breast cancer," the authors conclude.
The research was supported in part by NuView Inc.
Diabetes & Endocrinology
Copyright © 2009 ScoutNews, LLC. All rights reserved.